BioCryst Pharmaceuticals (BCRX) opened 2026 with Q1 revenue of US$156.4 million and a basic EPS loss of US$2.98, compared with Q1 2025 revenue of US$145.5 million and essentially breakeven EPS of US$0.00. Over the same period, trailing 12 month EPS shifted from a profit of US$1.26 to a loss of US$2.10. Over the past year, revenue on a trailing 12 month basis moved from US$503.5 million to US$885.7 million, while net income moved from a profit of US$263.9 million in 2025 Q4 to a loss of US$458.0 million in 2026 Q1. These changes put the focus squarely on how sustainable recent margin pressure may be.

See our full analysis for BioCryst Pharmaceuticals.

With the headline numbers on the table, the next step is to see how these results line up with the widely followed growth, risk, and profitability narratives around BioCryst, and where those stories might need updating.

TTM swings from US$263.9m profit to US$458.0m loss

• On a trailing 12 month basis, net income moved from a profit of US$263.9 million in 2025 Q4 to a loss of US$457.983 million in 2026 Q1, while TTM revenue increased from US$874.837 million to US$885.716 million over the same points in time.
• Consensus narrative expects revenue of about US$900.1 million and earnings of US$91.0 million by 2029, which contrasts with the current TTM loss of US$457.983 million and highlights a gap between the recent earnings swing and the medium term earnings profile that analysts are using in their models.
  • Analysts are working off a 5 year annualized earnings growth figure of roughly 29.5% and a reported move into profitability over the last year, yet the most recent TTM snapshot has moved back to a loss, so readers need to weigh which period feels more representative.
  • With analysts expecting margins to shrink from 30.2% to 10.1% by 2029, the current net loss reinforces the risk that profitability could be more volatile than the smoother earnings path implied in the consensus narrative.

Quarterly profit of US$245.8m to loss of US$721.8m

• Looking at individual quarters, net income excluding extra items shifted from a profit of US$245.845 million in Q4 2025 to a loss of US$721.812 million in Q1 2026, while revenue over those two quarters changed from US$406.555 million to US$156.413 million.
• Bears highlight concentration and pricing risks around ORLADEYO and worry about long term revenue pressure, and the sharp move from a quarterly profit of US$245.845 million to a loss of US$721.812 million gives that cautious view concrete earnings volatility to point to.
  • Bearish analysts assume revenue could decline by 1.2% per year over the next 3 years and margins could shrink from 30.2% to 4.0%, which lines up with the idea that today’s large quarterly loss could reflect pressure on profitability if pricing or competition tighten.
  • The fact that revenue was US$159.395 million and US$163.353 million in Q3 and Q2 2025, compared with US$156.413 million in Q1 2026, shows that recent quarterly revenue has stayed in a fairly tight band while earnings have swung widely, which bearish investors may read as cost or margin sensitivity rather than purely top line driven.

Skeptics point to the earnings volatility and reliance on a single drug, while bulls focus on the ORLADEYO franchise and pipeline potential, so if you want to see how that optimistic camp joins these numbers to its thesis, 🐂 BioCryst Pharmaceuticals Bull Case.

Low 8.7x P/E versus DCF fair value of US$76.78

• The stock trades on a trailing P/E of 8.7x compared with a DCF fair value estimate of US$76.78 and an analyst price target of US$21.20, while the current share price is US$8.83, which the data describes as about 88.3% below the internal DCF estimate.
• Bulls argue that strong ORLADEYO uptake and an expanding rare disease pipeline justify a higher valuation, and the combination of an 8.7x P/E with a DCF fair value of US$76.78 and a US$21.20 analyst target is exactly what they point to when they say the market is underpricing those growth options.
  • The P/E gap versus the US biotech industry at 17.2x and peer average at 20.2x suggests the stock trades at a discount to many comparables, which bullish investors see as inconsistent with reported 5 year annualized earnings growth of roughly 29.5% and past profitability.
  • At the same time, negative shareholders’ equity on the trailing 12 month view and a high level of debt are real balance sheet risks, so readers weighing the bullish case need to decide whether the combination of growth history and valuation discount compensates enough for those capital structure concerns.

If you want to see how bullish investors connect ORLADEYO growth, the pipeline, and this valuation gap into a full thesis, 🐻 BioCryst Pharmaceuticals Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for BioCryst Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

After reading both the cautious and optimistic angles, the real question is where you land. Move quickly, stress test the thesis against the data, and weigh the 4 key rewards and 3 important warning signs.

See What Else Is Out There

BioCryst’s swing from a TTM profit of US$263.9 million to a loss of US$458.0 million, alongside negative shareholders’ equity and high debt, highlights meaningful balance sheet and earnings risk.

If that level of volatility makes you uneasy, it may be useful to review stocks screened for stronger finances and steadier foundations through the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.